Researchers performed a randomised, double-blind, dose-response, phase 2 trial at an outpatient psychiatric clinic in the USA, which included service personnel who were 18 years or older, with chronic PTSD duration of 6 months or more, and who had a Clinician-Administered PTSD Scale (CAPS-IV) total score of 50 or greater. They found that effective doses of MDMA that were administered in a controlled setting, along with adjunctive psychotherapy, were well tolerated and were effective at reducing the symptoms of post-traumatic stress disorder.
Alternative Analysis of the Relative Risk from MDMA Use: "Nutt et al. (2007) attempted to compare the relative dangers of the main types of psychosocial drug, using a series of subjective rating scales. Heroin and cocaine were graded as the two most harmful drugs, whereas Ecstasy/MDMA emerged as one of the least harmful (18th out of 20). Unfortunately, it was unclear how this low harm rating score for Ecstasy/MDMA was given, as they cited no empirical research studies or reviews. Instead, Nutt et al.